Nicox SA, an international company specializing in ophthalmology, today announces development and partnership plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
• Commercial potential for NCX 470 in the United States as a new alternative treatment for the reduction of intraocular pressure suggested by the results of the Mont Blanc phase 3 study
• Plans to generate clinical data to demonstrate the potential beneficial effects of NCX 470 on the retina to add significant therapeutic value to the product profile in glaucoma
• Optimization of the value of the NCX 470 with potential future targeted commercial partnerships in the United States and Japan